# Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain

> **NCT02452112** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mundipharma (China) Pharmaceutical Co. Ltd** · enrollment: 243 (actual)

## Conditions studied

- Herpes Zoster Pain

## Interventions

- **DRUG:** 5% Lidocaine patch
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02452112
- **Lead sponsor:** Mundipharma (China) Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-02
- **Primary completion:** 2015-12-30
- **Final completion:** 2016-10-30
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452112, "Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02452112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*